Radiance Therapeutics is developing a next-generation beta therapy device for ophthalmic scar prophylaxis.
This therapeutic modality has been validated in 4 randomised controlled trials from preeminent ophthalmic research teams. Applied topically at the time of surgery, beta therapy has been shown to significantly improve glaucoma filtration surgery outcomes. The most recent of these studies reported odds ratios indicating that beta therapy patients were five and a half times more likely to experience lower IOP at the end of one year than patients treated with antimetabolite mitomycin-C.
Thanks to the generosity of our sponsors, registration for our 2021 virtual forums is complimentary for all delegates.